Parallel Advisors LLC Acquires 85,430 Shares of Arcus Biosciences Inc (NYSE:RCUS)
Parallel Advisors LLC increased its holdings in shares of Arcus Biosciences Inc (NYSE:RCUS) by 13,668.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,055 shares of the company’s stock after purchasing an additional 85,430 shares during the quarter. Parallel Advisors LLC’s holdings in Arcus Biosciences were worth $783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. EcoR1 Capital LLC lifted its holdings in Arcus Biosciences by 50.3% in the second quarter. EcoR1 Capital LLC now owns 1,488,205 shares of the company’s stock valued at $11,787,000 after acquiring an additional 498,059 shares during the period. BlackRock Inc. lifted its holdings in Arcus Biosciences by 22.1% in the second quarter. BlackRock Inc. now owns 2,236,133 shares of the company’s stock valued at $17,777,000 after acquiring an additional 404,432 shares during the period. Morgan Stanley lifted its holdings in Arcus Biosciences by 879.2% in the second quarter. Morgan Stanley now owns 98,806 shares of the company’s stock valued at $785,000 after acquiring an additional 88,716 shares during the period. Citadel Advisors LLC lifted its holdings in Arcus Biosciences by 296.9% in the second quarter. Citadel Advisors LLC now owns 69,537 shares of the company’s stock valued at $553,000 after acquiring an additional 52,018 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Arcus Biosciences by 5.5% in the second quarter. JPMorgan Chase & Co. now owns 515,262 shares of the company’s stock valued at $3,983,000 after acquiring an additional 26,709 shares during the period. 46.62% of the stock is currently owned by hedge funds and other institutional investors.
RCUS traded down $0.22 during midday trading on Friday, reaching $7.38. The company had a trading volume of 2,541 shares, compared to its average volume of 298,614. The business has a 50-day moving average of $8.46 and a two-hundred day moving average of $8.56. The company has a market cap of $383.30 million, a P/E ratio of -5.22 and a beta of 0.99. Arcus Biosciences Inc has a 1 year low of $6.30 and a 1 year high of $13.77.
A number of research firms have weighed in on RCUS. ValuEngine raised Arcus Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Mizuho restated a “buy” rating on shares of Arcus Biosciences in a research report on Sunday, October 20th. Finally, Zacks Investment Research cut Arcus Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Arcus Biosciences has a consensus rating of “Buy” and an average price target of $16.69.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Further Reading: Stocks Increasing Dividends
Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences Inc (NYSE:RCUS).
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.